COVID-19 Critical Intelligence Unit: Sotrovimab

In brief

Sotrovimab

21 January 2022

Introduction

• Sotrovimab (XEVDUY), is a monoclonal antibody treatment for COVID-19.¹
• Monoclonal antibodies are proteins, made in the laboratory, that mimic the immune system. They bind to a specific target – in the case of sotrovimab, to the spike protein of SARS-CoV-2. It appears to prevent membrane fusion after the virus binds to the human ACE2 receptor.²

Regulatory context – Australia

• Sotrovimab is provisionally approved and included in the Australian Register of Therapeutic Goods (ARTG). It is for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with COVID-19 who do not require initiation of oxygen due to COVID-19 and who are at increased risk of progression to hospitalisation or death.¹
• The Advisory Committee on Medicines (ACM) notes that patient selection or stratification should consider comorbidities, particularly multiple combinations of comorbidities, such as: diabetes requiring medication, obesity, chronic kidney disease, congestive heart failure, chronic obstructive pulmonary disease, and asthma requiring medication. It confirmed that sotrovimab (XEVDUY) should not be used in hospitalised patients or those who require oxygen therapy due to COVID-19.¹
• The NSW Health model of care for the use of anti-SARS-CoV-2 monoclonal antibodies recommends that sotrovimab is preferred over casirivimab and imdevimab for treatment of the Omicron variant of concern.³

Regulatory context – international

• The UK Medicines and Healthcare products Regulatory Agency approved sotrovimab for use in people aged 12 years and older (weighing over 40kg) who have mild to moderate COVID-19 infection and at least one risk factor for developing severe illness (e.g. obesity, older age, diabetes, or heart disease).⁴
• The FDA issued emergency use authorisation of sotrovimab for treatment of mild-to-moderate COVID-19 in patients 12 years and older (weighing at least 40kg) at high risk for progression to severe COVID-19. Sotrovimab was not authorised for use in patients hospitalised due to COVID-19, requiring oxygen therapy due to COVID-19, or requiring an increase in baseline oxygen flow rate due to COVID-19.⁵,⁶
• The European Medicines Agency recommended authorising sotrovimab for treating COVID-19 in patients 12 years and older (and weighing over 40kg) who do not require supplemental oxygen and who are at increased risk of severe disease.⁷
• Health Canada has authorised sotrovimab for treatment of patients with mild to moderate COVID-19 infection at high risk of hospitalisation and/or death.⁸ Prescribers should consider national and international guidelines when assessing risk. Sotrovimab should be administered as soon as possible after the onset of symptoms and confirmation of COVID-19.⁹

In brief documents are not an exhaustive list of publications but aim to provide an overview of what is already known about a specific topic. This brief has not been peer-reviewed and should not be a substitute for individual clinical judgement, nor is it an endorsed position of NSW Health.
Clinical studies – research evidence

- Interim data from a phase 3 trial (COMET-ICE) show the risk of disease progression was reduced by 85%. The trial involved 583 adult outpatients with mild to moderate COVID-19 who were ≥55 years old or had at least one comorbidity (diabetes, obesity, chronic kidney disease, heart failure, COPD, or moderate to severe asthma).\(^\text{10}\)
  - Patients were randomised to receive a single intravenous infusion of 500mg of sotrovimab or placebo. The primary endpoint, progression of COVID-19 (hospitalisation for >24 hours or death) by day 29, occurred in 1% (3 out of 291) of patients who received sotrovimab and in 7% (21 out of 292) of those who received placebo (p=0.002).\(^\text{10}\)
  - Any adverse events occurred in 17% (73 out of 430) of those who received sotrovimab and 19% (19 out of 438) of those who received placebo.
  - Serious adverse event occurred in 2% (7 out of 430) of those who received sotrovimab and 6% (26 out of 438) of those who received placebo.
  - There were no deaths in the sotrovimab group and two deaths (<1%) in the placebo group.
- Full results from the COMET-ICE trial (preprint) show that sotrovimab can be an effective treatment option for non-hospitalised patients with mild to moderate COVID-19.
  - All-cause hospitalisation longer than 24 hours or death: 1% (6 out of 528) with sotrovimab and 6% (30 out of 529) with placebo; reduced by 79%.
  - Emergency room visits, hospitalisation of any duration, or death: 2% (13 out of 528) with sotrovimab and 7% (39 out of 529) with placebo; reduced by 66%.
  - Severe/critical respiratory COVID-19: 1% (7 out of 528) with sotrovimab and 5% (28 out of 529) with placebo; reduced by 74%.
  - Required high-flow oxygen, oxygen via nonrebreather mask, or mechanical ventilation: 0% (0 out of 528) with sotrovimab and 3% (14 out of 529) with placebo.
  - Similar rates of adverse events in both the sotrovimab and the placebo groups.\(^\text{11}\)
- A phase 3 trial, COMET-TAIL, data showed that intramuscular administration of sotrovimab had a similar efficacy to intravenous administration for the early treatment of mild-to-moderate COVID-19 in high-risk, non-hospitalised adults and adolescents (12 years of age and older). The COMET-TAIL trial enrolled 983 patients up to seven days after onset of symptoms.
  - Progression to hospitalisation for more than 24 hours or death through Day 29: 2.7% in the intramuscular arm and 1.3% in the intravenous arm.
  - Rates of serious adverse events and Grade 3-4 adverse events: similar in both arms and both were under 1%.\(^\text{12}\)
- A phase 2 trial, COMET-PEAK, data showed equivalence on the virological response between the intramuscular and intravenous administration of sotrovimab.\(^\text{12}\)

Dosage and administration

- The NSW Therapeutic Advisory group recommended dose is 500mg as a single dose intravenous infusion over 30 minutes.\(^\text{13}\)
  - If the solution cannot be used immediately after dilution, it can be refrigerated for up to 24 hours or left at room temperature for up to six hours, including infusion time.
- The models of care for the use of anti-SARS-CoV-2 monoclonal antibodies in NSW recommends that sotrovimab infusion may be delivered in a range of settings, including
inpatient, outpatient or outreach settings, depending on local requirements. The choice of setting should consider storage and transport of the drug in respect of the cold chain, preparation of the infusion and administration and disposal.3

- A living WHO guideline on drugs for COVID-19 suggests a single dose of 500mg intravenous infusion over 30 minutes.14

**Action against SARS-CoV-2 variants**

- Sotrovimab appears to retain activity against Alpha; Beta; Gamma; Epsilon; Iota; and Delta variants of SARS-CoV-2.6
- Treatment-emergent epitope variants were detected in eight patients who received sotrovimab in COMET-ICE; some of these substitutions conferred reduced susceptibility to the drug.10
- Several preprint studies found that sotrovimab retained neutralising activity and potency against the Omicron variant of SARS-CoV-2.15

**Adverse Effects**

- The most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (2%) and diarrhea (1%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.16

**Care delivery models**

- The Australian National COVID-19 Clinical Evidence Taskforce recommends basing decisions about the appropriateness of sotrovimab treatment on the individual risk of severe disease and COVID-19 vaccination status. Sotrovimab should be considered in unvaccinated or partially vaccinated patients and patients who are immunosuppressed. Sotrovimab should not be routinely used in fully vaccinated patients unless immunosuppressed. Treatment should begin within five days of symptom onset.17
- The NSW Health model of care for the use of monoclonal antibodies recommends sotrovimab for the treatment of patients with mild to moderate COVID-19 who are at risk of progressing to severe disease. Patients who are immunosuppressed and other at-risk cohorts should be prioritised. Sotrovimab treatment is not routinely recommended for fully vaccinated patients.3
- In the UK, the NHS contacts suitable candidates for sotrovimab with 24 hours of a positive PCR test result. Sotrovimab is recommended within five days of symptom onset and given by infusion. Where sotrovimab is contraindicated or administration is not possible, patients may be treated with a five-day course of molnupiravir.18

**Number needed to treat**

- According to the TGA and the FDA, the estimated number needed to treat is 16 outpatients at high risk for progression to severe COVID-19 to prevent one hospitalisation or death.5, 19

To inform this brief, PubMed and Google searches were conducted using terms related to sotrovimab on 18 November 2021. An updated search was conducted on 14 January 2022.
References


Evidence checks are archived a year after the date of publication.